Monoclonal antibody treatment by Eli Lilly found to cut risk of serious COVID-19, drugmaker reports




  • In Health
  • 2021-01-21 13:00:17Z
  • By USA TODAY
 

A drug developed by Eli Lilly and Company dramatically reduced the risk of developing symptomatic COVID-19 among nursing home residents, the company found.

Of 299 residents, half of whom received a placebo, those randomized to receive the drug bamlanivimab had up to an 80% lower risk of contracting COVID-19, according to a study that has not yet been published.

Health care providers at the same nursing homes also were statistically less likely to contract symptomatic COVID-19 after receiving bamlanivimab, which was delivered in a 4,200 mg dose. Among 41 residents who already tested positive for the virus, none died after receiving the drug compared to 4 deaths in the placebo group.

Tracking COVID-19 vaccine distribution: How many people in the US have received a shot?

The BLAZE-2 COVID-19 prevention trial was conducted in partnership with the National Institute of Allergy and Infectious Diseases. Bamlanivimab, which is authorized for use in high-risk COVID-19 patients with mild to moderate disease, is a so-called monoclonal antibody - meaning it provides a manufactured version of antibodies the immune system naturally makes to fight an infection.

"The results of this innovative study further support the belief that bamlanivimab - and potentially other monoclonal antibodies - can reduce symptoms and may even prevent COVID-19," Dr. Myron S. Cohen, who helped lead the study and directs the Institute for Global Health and Infectious Diseases at the University of North Carolina at Chapel Hill, said in a prepared statement.

"The antiviral activity seen with bamlanivimab treatment emphasizes the importance of early intervention to help counter the devastating impact the virus has had in this vulnerable population and other high-risk patients."

COVID, one year later: The first US case. The first death. The first outbreak at a nursing home.

The federal government has bought hundreds of thousands of doses of bamlanivimab and a similar drug from Regeneron, which former President Donald Trump received when he was sick with COVID-19.

Most of those doses have gone unused so far, because the drugs must be given to patients not yet sick enough to be hospitalized. They are also delivered via hour-long infusions at a time when patients are highly contagious.

More information on obtaining monoclonal antibodies is available at covid.infusioncenter.org

Contact Karen Weintraub at kweintraub@usatoday.com

Health and patient safety coverage at USA TODAY is made possible in part by a grant from the Masimo Foundation for Ethics, Innovation and Competition in Healthcare. The Masimo Foundation does not provide editorial input.

This article originally appeared on USA TODAY: Eli Lilly reports its monoclonal antibody treatment cuts COVID-19 risk

COMMENTS

More Related News

Remote-Working Consultants and Bankers Party Hard in No-Lockdown Zanzibar
Remote-Working Consultants and Bankers Party Hard in No-Lockdown Zanzibar
  • World
  • 2021-03-08 09:59:29Z

ReutersZANZIBAR, Tanzania-"I fully support lockdowns and COVID restrictions, I just choose not to follow any of them" said Simon, who knew he'd be fired if...

Cuomo defiant as top New York lawmakers call on him to quit
Cuomo defiant as top New York lawmakers call on him to quit
  • World
  • 2021-03-07 19:05:47Z

The two top Democrats in New York's legislature withdrew their support for Gov. Andrew Cuomo on Sunday amid mounting allegations of sexual harassment and...

A Family
A Family's Search for Answers: Did Their Brother Die of COVID?

MIAMI - The Hidalgo siblings buried their younger brother, Patrick, six days after he had texted them in the middle of the night last March to say that...

Adaptive
Adaptive's T-Detect COVID Test Cleared For Emergency Use In US; Shares Pop 18%

Adaptive Biotechnologies' T-Detect COVID diagnostic test, which was designed to confirm a recent or prior COVID-19 infection, has been authorized for...

6 takeaways from the Senate
6 takeaways from the Senate's approval of Joe Biden's $1.9 trillion COVID-19 relief bill

What it means for Joe Biden politically for millions of Americans awaiting relief.

Leave a Comment

Your email address will not be published. Required fields are marked with *

Cancel reply

Comments

Top News: Health